Peripheral Artery Disease Market By Product Type (Devices, Drugs), By End User (Hospitals, Specialty Clinics): Global Opportunity Analysis and Industry Forecast, 2024-2035
The global peripheral artery disease market was valued at $4.5 billion in 2023, and is estimated t%li%reach $10.8 billion by 2035, growing at a CAGR of 7.7% from 2024 t%li%2035. Peripheral artery disease is a condition characterized by the narrowing or blockage of arteries that supply blood t%li%the limbs, typically the legs. This occurs due t%li%the buildup of fatty deposits (plaques) in the arteries, a process known as atherosclerosis. As a result, blood flow t%li%the legs is restricted, leading t%li%symptoms such as leg pain, cramping, numbness, and weakness, particularly during physical activity. Treatment for peripheral artery disease aims t%li%manage symptoms, prevent complications, and improve blood flow. Procedures or surgeries may be required t%li%open blocked arteries and restore blood flow. These can include angioplasty (where a balloon is used t%li%widen the artery) or stent placement (t%li%keep the artery open).
The peripheral artery disease market growth is attributed t%li%rise in geriatric population, and technological advancements in minimally invasive surgical technology. According t%li%2022 report by World Health Organization, it was estimated that, the geriatric population (aged 60 and above) is expected t%li%contribute about 22% of global population. As people age, the risk of developing peripheral artery disease rises, especially among those with other cardiovascular risk factors such as diabetes, hypertension, and smoking history. With populations in many countries experiencing a demographic shift towards older age brackets, the incidence and prevalence of peripheral artery disease are expected t%li%escalate. According t%li%the 2023 report by the National Library of Medicine, it was reported that incidence of peripheral artery disease increases t%li%as high as 20% in people over the age of 70. Thus, as the geriatric population has a higher incidence rate of peripheral artery disease, the rise in geriatric population is expected t%li%positively impact the growth of peripheral artery disease market.In addition, technological advancements in minimally invasive procedures have emerged as a major driver for the peripheral artery disease market, transforming the landscape of diagnosis and treatment. Minimally invasive techniques, such as angioplasty, stenting, and atherectomy, have revolutionized the management of peripheral artery disease by offering safer and more effective alternatives t%li%traditional open surgeries. These procedures involve smaller incisions, reduced trauma t%li%surrounding tissues, shorter recovery times, and lower risk of complications compared t%li%conventional surgical approaches. For instance, Medtronic Plc, a leading medical devices company, provides a complete SE vascular stent system. The complete SE vascular stent system is designed t%li%treat peripheral arterial disease in the superficial femoral arteries and proximal popliteal arteries. The stent is designed t%li%open clogged arteries and restore blood flow by providing support t%li%the artery after angioplasty. Thus, the advantages of minimally invasive procedures such as shorter hospital stays and reduced physical trauma (caused in traditional open surgery) are expected t%li%drive the growth of the market.The peripheral artery disease market is segmented by product type, end user, and region. By product type the market is bifurcated int%li%drugs and devices. By end user, the market is divided int%li%hospitals, specialized clinics and ambulatory surgeries centers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA). Major key players that operate in the peripheral artery disease market are Philips N.V., Braun Melsungen AG, Medtronic, Bayer AG, Boston Scientific Corporation, Becton Dickinson and Company, Terum%li%Medical Corporation, Biotronik, Cardinal Health, Abbott. Key players have adopted product approval as a key developmental strategy t%li%improve the product portfoli%li%of the peripheral artery disease marketKey Benefits For Stakeholders
By Product Type
The peripheral artery disease market growth is attributed t%li%rise in geriatric population, and technological advancements in minimally invasive surgical technology. According t%li%2022 report by World Health Organization, it was estimated that, the geriatric population (aged 60 and above) is expected t%li%contribute about 22% of global population. As people age, the risk of developing peripheral artery disease rises, especially among those with other cardiovascular risk factors such as diabetes, hypertension, and smoking history. With populations in many countries experiencing a demographic shift towards older age brackets, the incidence and prevalence of peripheral artery disease are expected t%li%escalate. According t%li%the 2023 report by the National Library of Medicine, it was reported that incidence of peripheral artery disease increases t%li%as high as 20% in people over the age of 70. Thus, as the geriatric population has a higher incidence rate of peripheral artery disease, the rise in geriatric population is expected t%li%positively impact the growth of peripheral artery disease market.In addition, technological advancements in minimally invasive procedures have emerged as a major driver for the peripheral artery disease market, transforming the landscape of diagnosis and treatment. Minimally invasive techniques, such as angioplasty, stenting, and atherectomy, have revolutionized the management of peripheral artery disease by offering safer and more effective alternatives t%li%traditional open surgeries. These procedures involve smaller incisions, reduced trauma t%li%surrounding tissues, shorter recovery times, and lower risk of complications compared t%li%conventional surgical approaches. For instance, Medtronic Plc, a leading medical devices company, provides a complete SE vascular stent system. The complete SE vascular stent system is designed t%li%treat peripheral arterial disease in the superficial femoral arteries and proximal popliteal arteries. The stent is designed t%li%open clogged arteries and restore blood flow by providing support t%li%the artery after angioplasty. Thus, the advantages of minimally invasive procedures such as shorter hospital stays and reduced physical trauma (caused in traditional open surgery) are expected t%li%drive the growth of the market.The peripheral artery disease market is segmented by product type, end user, and region. By product type the market is bifurcated int%li%drugs and devices. By end user, the market is divided int%li%hospitals, specialized clinics and ambulatory surgeries centers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA). Major key players that operate in the peripheral artery disease market are Philips N.V., Braun Melsungen AG, Medtronic, Bayer AG, Boston Scientific Corporation, Becton Dickinson and Company, Terum%li%Medical Corporation, Biotronik, Cardinal Health, Abbott. Key players have adopted product approval as a key developmental strategy t%li%improve the product portfoli%li%of the peripheral artery disease marketKey Benefits For Stakeholders- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the peripheral artery disease market analysis from 2023 t%li%2035 t%li%identify the prevailing peripheral artery disease market opportunities.
- The market research is offered along with information related t%li%key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers t%li%enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the peripheral artery disease market segmentation assists t%li%determine the prevailing market opportunities.
- Major countries in each region are mapped according t%li%their revenue contribution t%li%the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global peripheral artery disease market trends, key players, market segments, application areas, and market growth strategies.
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting t%li%16 analyst hours t%li%solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent t%li%3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.Possible Customization with this report (with additional cost and timeline, please talk t%li%the sales executive t%li%know more)
- Regulatory Guidelines
- Additional company profiles with specific t%li%client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
By Product Type
- Devices
- Devices type
- Peripheral Angioplasty Balloons
- Peripheral Stents
- Peripheral Catheters
- Inferior Vena Cava Filters
- Plaque Modification Devices
- Hemodynamic Flow Alteration Devices
- Peripheral Accessories
- Drugs
- Drug Type
- Antiplatelet medicines
- Statins
- Anti Hypertensive Medication
- Others
- Specialty Clinics
- Hospitals
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Koninklijke Philips N.V.
- B. Braun Melsungen AG
- Medtronic
- Bayer AG
- Boston Scientific Corporation
- Becton Dickinson and Company
- Terum
- Medical Corporation
- Biotronik SE & Co. KG
- Cardinal Health
- Abbott Laboratories
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Devices
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Devices Peripheral Artery Disease Market by Devices type
4.3. Drugs
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.3.4. Drugs Peripheral Artery Disease Market by Drug Type
CHAPTER 5: PERIPHERAL ARTERY DISEASE MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Specialty Clinics
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: PERIPHERAL ARTERY DISEASE MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by Product Type
6.2.3. Market size and forecast, by End User
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Market size and forecast, by Product Type
6.2.4.1.2. Market size and forecast, by End User
6.2.4.2. Canada
6.2.4.2.1. Market size and forecast, by Product Type
6.2.4.2.2. Market size and forecast, by End User
6.2.4.3. Mexico
6.2.4.3.1. Market size and forecast, by Product Type
6.2.4.3.2. Market size and forecast, by End User
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by Product Type
6.3.3. Market size and forecast, by End User
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Market size and forecast, by Product Type
6.3.4.1.2. Market size and forecast, by End User
6.3.4.2. France
6.3.4.2.1. Market size and forecast, by Product Type
6.3.4.2.2. Market size and forecast, by End User
6.3.4.3. UK
6.3.4.3.1. Market size and forecast, by Product Type
6.3.4.3.2. Market size and forecast, by End User
6.3.4.4. Italy
6.3.4.4.1. Market size and forecast, by Product Type
6.3.4.4.2. Market size and forecast, by End User
6.3.4.5. Spain
6.3.4.5.1. Market size and forecast, by Product Type
6.3.4.5.2. Market size and forecast, by End User
6.3.4.6. Rest of Europe
6.3.4.6.1. Market size and forecast, by Product Type
6.3.4.6.2. Market size and forecast, by End User
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by Product Type
6.4.3. Market size and forecast, by End User
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Market size and forecast, by Product Type
6.4.4.1.2. Market size and forecast, by End User
6.4.4.2. China
6.4.4.2.1. Market size and forecast, by Product Type
6.4.4.2.2. Market size and forecast, by End User
6.4.4.3. Australia
6.4.4.3.1. Market size and forecast, by Product Type
6.4.4.3.2. Market size and forecast, by End User
6.4.4.4. India
6.4.4.4.1. Market size and forecast, by Product Type
6.4.4.4.2. Market size and forecast, by End User
6.4.4.5. South Korea
6.4.4.5.1. Market size and forecast, by Product Type
6.4.4.5.2. Market size and forecast, by End User
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Market size and forecast, by Product Type
6.4.4.6.2. Market size and forecast, by End User
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by Product Type
6.5.3. Market size and forecast, by End User
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Market size and forecast, by Product Type
6.5.4.1.2. Market size and forecast, by End User
6.5.4.2. Saudi Arabia
6.5.4.2.1. Market size and forecast, by Product Type
6.5.4.2.2. Market size and forecast, by End User
6.5.4.3. South Africa
6.5.4.3.1. Market size and forecast, by Product Type
6.5.4.3.2. Market size and forecast, by End User
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Market size and forecast, by Product Type
6.5.4.4.2. Market size and forecast, by End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Koninklijke Philips N.V.
8.1.1. Company overview
8.1.2. Key executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. B. Braun Melsungen AG
8.2.1. Company overview
8.2.2. Key executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Medtronic
8.3.1. Company overview
8.3.2. Key executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Bayer AG
8.4.1. Company overview
8.4.2. Key executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Boston Scientific Corporation
8.5.1. Company overview
8.5.2. Key executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Becton Dickinson and Company
8.6.1. Company overview
8.6.2. Key executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Terumo Medical Corporation
8.7.1. Company overview
8.7.2. Key executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Biotronik SE & Co. KG
8.8.1. Company overview
8.8.2. Key executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Cardinal Health
8.9.1. Company overview
8.9.2. Key executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Abbott Laboratories
8.10.1. Company overview
8.10.2. Key executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Devices
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Devices Peripheral Artery Disease Market by Devices type
4.3. Drugs
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.3.4. Drugs Peripheral Artery Disease Market by Drug Type
CHAPTER 5: PERIPHERAL ARTERY DISEASE MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Specialty Clinics
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: PERIPHERAL ARTERY DISEASE MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by Product Type
6.2.3. Market size and forecast, by End User
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Market size and forecast, by Product Type
6.2.4.1.2. Market size and forecast, by End User
6.2.4.2. Canada
6.2.4.2.1. Market size and forecast, by Product Type
6.2.4.2.2. Market size and forecast, by End User
6.2.4.3. Mexico
6.2.4.3.1. Market size and forecast, by Product Type
6.2.4.3.2. Market size and forecast, by End User
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by Product Type
6.3.3. Market size and forecast, by End User
6.3.4. Market size and forecast, by country
6.3.4.1. Germany
6.3.4.1.1. Market size and forecast, by Product Type
6.3.4.1.2. Market size and forecast, by End User
6.3.4.2. France
6.3.4.2.1. Market size and forecast, by Product Type
6.3.4.2.2. Market size and forecast, by End User
6.3.4.3. UK
6.3.4.3.1. Market size and forecast, by Product Type
6.3.4.3.2. Market size and forecast, by End User
6.3.4.4. Italy
6.3.4.4.1. Market size and forecast, by Product Type
6.3.4.4.2. Market size and forecast, by End User
6.3.4.5. Spain
6.3.4.5.1. Market size and forecast, by Product Type
6.3.4.5.2. Market size and forecast, by End User
6.3.4.6. Rest of Europe
6.3.4.6.1. Market size and forecast, by Product Type
6.3.4.6.2. Market size and forecast, by End User
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by Product Type
6.4.3. Market size and forecast, by End User
6.4.4. Market size and forecast, by country
6.4.4.1. Japan
6.4.4.1.1. Market size and forecast, by Product Type
6.4.4.1.2. Market size and forecast, by End User
6.4.4.2. China
6.4.4.2.1. Market size and forecast, by Product Type
6.4.4.2.2. Market size and forecast, by End User
6.4.4.3. Australia
6.4.4.3.1. Market size and forecast, by Product Type
6.4.4.3.2. Market size and forecast, by End User
6.4.4.4. India
6.4.4.4.1. Market size and forecast, by Product Type
6.4.4.4.2. Market size and forecast, by End User
6.4.4.5. South Korea
6.4.4.5.1. Market size and forecast, by Product Type
6.4.4.5.2. Market size and forecast, by End User
6.4.4.6. Rest of Asia-Pacific
6.4.4.6.1. Market size and forecast, by Product Type
6.4.4.6.2. Market size and forecast, by End User
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by Product Type
6.5.3. Market size and forecast, by End User
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Market size and forecast, by Product Type
6.5.4.1.2. Market size and forecast, by End User
6.5.4.2. Saudi Arabia
6.5.4.2.1. Market size and forecast, by Product Type
6.5.4.2.2. Market size and forecast, by End User
6.5.4.3. South Africa
6.5.4.3.1. Market size and forecast, by Product Type
6.5.4.3.2. Market size and forecast, by End User
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Market size and forecast, by Product Type
6.5.4.4.2. Market size and forecast, by End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Koninklijke Philips N.V.
8.1.1. Company overview
8.1.2. Key executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. B. Braun Melsungen AG
8.2.1. Company overview
8.2.2. Key executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Medtronic
8.3.1. Company overview
8.3.2. Key executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Bayer AG
8.4.1. Company overview
8.4.2. Key executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Boston Scientific Corporation
8.5.1. Company overview
8.5.2. Key executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Becton Dickinson and Company
8.6.1. Company overview
8.6.2. Key executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Terumo Medical Corporation
8.7.1. Company overview
8.7.2. Key executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. Biotronik SE & Co. KG
8.8.1. Company overview
8.8.2. Key executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Cardinal Health
8.9.1. Company overview
8.9.2. Key executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Abbott Laboratories
8.10.1. Company overview
8.10.2. Key executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
